Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indalpine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 1.00 |
| ▸ | BCHE | P06276 | 4/20 | 0.58 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indalpine SCHEMBL29604957 | 1.00 | SLC6A4 (1.00) | SLC6A4BCHEHTR2CMPOCYP1A2 | |
| Indalpine SCHEMBL3863561 | 1.00 | SLC6A4 (1.00) | SLC6A4BCHEHTR2CMPOCYP1A2 | |
| Indalpine SCHEMBL141694 | 0.98 | SLC6A4 (0.97) | SLC6A4BCHEHTR2CMPOCYP1A2 | |
| SCHEMBL18426580 | 0.86 | SLC6A4 (0.76) | SLC6A4BCHEACHE | |
| SCHEMBL1998835 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR2CCYP3A4HTR6ADRB2 | |
| SCHEMBL30592374 | 0.86 | SLC6A4 (1.00) | SLC6A4HTR2CCYP3A4HTR6ADRB2 | |
| SCHEMBL10951080 | 0.83 | SLC6A4 (0.71) | SLC6A4BCHEHTR2CMPOCYP1A2 | |
| SCHEMBL8240955 | 0.82 | SLC6A4 (0.69) | SLC6A4BCHEHTR2A | |
| SCHEMBL9571078 | 0.81 | SLC6A4 (0.67) | SLC6A4BCHEHTR2CMPOCYP1A2 | |
| SCHEMBL17367855 | 0.80 | SLC6A4 (0.72) | SLC6A4HTR2CHTR1DHTR1BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3857 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| US-20250295674-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. | 2025-09-25 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4536231-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2025-04-16 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| EP-3630102-B1 | FORMULATIONS FOR TREATMENT OF POST-TRAUMATIC STRESS DISORDER | GLYTECH LLC (US) | 2024-08-14 | — | — | EP | claimed |
| US-5589512-A | DIAGNOSIS OF PSYCHOLOGICAL DISORDERS | NORDEN MICHAEL J (US) | 1996-12-31 | — | — | US | claimed |
| WO-1996041633-A1 | METHODS OF TREATING COLD AND ALLERGIC RHINITIS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | WO | claimed |
| EP-0747049-A1 | Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis | ELI LILLY AND COMPANY (US) | 1996-12-11 | — | — | EP | claimed |
| WO-1996031172-A1 | VETERINARY METHOD FOR CLINICALLY MODIFYING THE BEHAVIOR OF DOGS EXHIBITING CANINE AFFECTIVE AGGRESSION | TRUSTEES OF TUFTS COLLEGE (US) | 1996-10-10 | — | — | WO | claimed |
| WO-1996029074-A1 | METHODS OF TREATING OR PREVENTING PAIN OR NOCICEPTION | ELI LILLY AND COMPANY (US) | 1996-09-26 | — | — | WO | claimed |
| US-5554383-A | ADMINISTERING SELECTIVE SEROTONIN REUPTAKE INHIBITOR | TRUSTEES OF TUFTS COLLEGE (US) | 1996-09-10 | — | — | US | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |